SIR 2024
Men's Health
Yonatan B. Babore, BA (he/him/his)
Medical Student
Division of Interventional Radiology, Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Financial relationships: Full list of relationships is listed on the CME information page.
Gyan C. Moorthy, MS
Medical Student
Perelman School of Medicine at the University of Pennsylvania
Disclosure information not submitted.
Xin Li, MD
Resident
Hospital of the University of Pennsylvania
Financial relationships: Full list of relationships is listed on the CME information page.
Ansar Z. Vance, MD, MSEd
Attending Physician
University of Pennsylvania
Financial relationships: Full list of relationships is listed on the CME information page.
Timothy W.I Clark, MD, MS
Professor
University of Pennsylvania
Financial relationships: Full list of relationships is listed on the CME information page.
Over a four-year period, a prospectively maintained database identified 17 PAEs performed in men a mean of 48.4 months (range 33-93) following UroLift. These cases were compared to a contemporaneous control group of 49 men with prostate volumes < 100 g who underwent PAE; a 100 g threshold was utilized as these men would otherwise have been ineligible for UroLift themselves. International Prostate Symptom Severity (IPSS) scores were compared with the Mann-Whitney U test.
Results:
Mean age of the Urolift cases was 67.0 years (range 57–82) and 67.6 years (range 54–83 years) among the controls (p=0.83). At baseline, mean prostate volume was 81 g among the prostatic lift patients and 70 g among controls (p=0.45). Mean IPSS baseline scores were 24.0 (range 15-32) among prostatic lift patients prior to PAE and 22.4 (range 8-34) among controls (p= 0.51). Post-intervention IPSS scores were collected at a mean of 3.1 months (range 0.33-5 months) following PAE for the Urolift patients and 4.0 (range 0.23-29 months) months for the control patients (p=0.36). Mean IPSS reduction following PAE was -14.4 (range -26-2) among Urolift patients and -11.3 (range -28-9) among controls (p=0.35).
Conclusion: Men with prior failure of UroLift experienced similar improvements in LUTS as men with no prior prostatic intervention.